The transaction is the second acquisition between Novartis and Harrow. The five medications acquired by Harrow include:
1. Ilevro: an anti-inflammatory eye drop for cataract surgery.
2. Nevanac: also an anti-inflammatory eye drop for cataract surgery.
3. Vigamox: an antibiotic eye drop for bacterial conjunctivitis.
4. Maxidex: a steroid eye drop for inflammatory conditions of the cornea.
5. Triesence: a steroid injection for the treatment of certain ophthalmic diseases.
Harrow will pay Novartis $130 million at closing, and an additional $45 million when Triesence becomes commercially available, which is expected in the second half of 2023.
During a six month transfer period, Novartis will continue to sell the medications in the U.S. Novartis will retain all sales rights outside of the U.S.
The transaction is expected to close in early 2023, subject to regulatory approvals, according to a Dec. 14 press release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.